This study will compare the immunogenicity and safety of the MeMuRu-OKA vaccine administered subcutaneously or using an alternative administration route.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
330
GSK Investigational Site
Bönnigheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Seroconversion rates after vaccination
Antibody titres; safety: solicited local/ general, unsolicited AEs (42 days), SAEs (whole study)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bretten, Baden-Wurttemberg, Germany
GSK Investigational Site
Ettenheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Karlsruhe, Baden-Wurttemberg, Germany
GSK Investigational Site
Kehl, Baden-Wurttemberg, Germany
GSK Investigational Site
Mannheim, Baden-Wurttemberg, Germany
GSK Investigational Site
Oberkirch, Baden-Wurttemberg, Germany
GSK Investigational Site
Offenburg, Baden-Wurttemberg, Germany
GSK Investigational Site
Schwäbisch Hall, Baden-Wurttemberg, Germany
GSK Investigational Site
Stuttgart, Baden-Wurttemberg, Germany
...and 10 more locations